Article by Charlie Taylor Irish Times, Monday 21 May 2018 Biosimilars are medicines that have no clinically meaningful difference from the original patented biologic medication
Medicines for Ireland has announced the appointment of Mylan Ireland Country Manager, Owen McKeon, as new chairperson of the organisation, taking over from Sandra Gannon
THE Government spent €57.5million on three name brand drugs despite cheaper, equally effective alternatives available. The HSE has forked out the cash this year on
Medicines for Ireland, the representative association for generic and biosimilar suppliers in Ireland, has cautioned that a promised new National Biosimilar Policy may lead to
Leading European experts will discuss existing policy and debate reforms, including the wider availability of adrenaline auto-injectors (AAIs) in European public spaces
Mairead McGuinness MEP, will host a breakfast briefing on the public health challenges of anaphylaxis.
ESMO 2017 INDUSTRY SATELLIE SYMPOSIUM: FRIDAY 8 SEPTEMBER 2017
18:00-20:00
PAMPLONA AUDITORIUM, HALL 4
IFEMA FERIA DE MADRID, SPAIN
A GROUP OF some of the biggest generic drug makers in Ireland are pushing for the HSE to change the way it decides how much to pay for medicines.
A National Medicines Strategy for Ireland providing a long-term roadmap for how Ireland procures, supplies and affords medicines for Irish patients, is one of the key proposals contained in Medicines for Ireland’s policy manifesto published today.
THE State has wasted hundreds of millions of euro on brand name drugs despite cheaper alternatives being available, it is claimed.
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
